Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced Research Projects Agency (DARPA), as the inaugural director of the Advanced Research Projects Agency for Health (ARPA-H). Announced by President Joe Biden with her official appointment on [...]
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging its limitations.
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro.
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.
As of October 16, 2025, the U.S. stock market is a tapestry woven with threads of robust corporate earnings, groundbreaking technological advancements, and persistent geopolitical and economic uncertainties. While the Dow Jones Industrial Average (DJIA), S&P 500, and Nasdaq Composite have demonstrated remarkable resilience, often pushing to new
Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is more accessible and efficient. This digital revolution, however, is unfolding amidst a complex landscape of groundbreaking scientific advancements and pervasive misinformation, making it crucial to discern genuine [...]
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have emerged as standout performers for dividend-seeking investors. As of October 15, 2025, these companies represent compelling examples of
